Knop FK - Search Results

1

Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetes.

Buse JB, Holst I, Knop FK, Kvist K, Thielke D, Pratley R. Buse JB, et al. Among authors: knop fk. Diabetes Obes Metab. 2021 Jul;23(7):1666-1671. doi: 10.1111/dom.14381. Epub 2021 May 4. Diabetes Obes Metab. 2021. PMID: 33764641 Free PMC article.

2

No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis.

Knop FK, Vilsbøll T, Larsen S, Madsbad S, Holst JJ, Krarup T. Knop FK, et al. Diabetes Care. 2003 Sep;26(9):2581-7. doi: 10.2337/diacare.26.9.2581. Diabetes Care. 2003. PMID: 12941722 Clinical Trial.

3

Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?

Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ, Krarup T. Knop FK, et al. Diabetes. 2007 Aug;56(8):1951-9. doi: 10.2337/db07-0100. Epub 2007 May 18. Diabetes. 2007. PMID: 17513701

4

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.

Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FK, Holst JJ. Hare KJ, et al. Among authors: knop fk. Diabetes. 2010 Jul;59(7):1765-70. doi: 10.2337/db09-1414. Epub 2010 Feb 11. Diabetes. 2010. PMID: 20150286 Free PMC article.

5

Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.

Aaboe K, Knop FK, Vilsbøll T, Deacon CF, Holst JJ, Madsbad S, Krarup T. Aaboe K, et al. Among authors: knop fk. Diabetes Obes Metab. 2010 Apr;12(4):323-33. doi: 10.1111/j.1463-1326.2009.01167.x. Diabetes Obes Metab. 2010. PMID: 20380653 Clinical Trial.

6

Incretin-based therapy and type 2 diabetes.

Hare KJ, Knop FK. Hare KJ, et al. Among authors: knop fk. Vitam Horm. 2010;84:389-413. doi: 10.1016/B978-0-12-381517-0.00015-1. Vitam Horm. 2010. PMID: 21094909 Review.

7

Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes.

Jimenez-Solem E, Rasmussen MH, Christensen M, Knop FK. Jimenez-Solem E, et al. Among authors: knop fk. Curr Opin Mol Ther. 2010 Dec;12(6):790-7. Curr Opin Mol Ther. 2010. PMID: 21154170

8

Impaired regulation of the incretin effect in patients with type 2 diabetes.

Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsbøll T. Bagger JI, et al. Among authors: knop fk. J Clin Endocrinol Metab. 2011 Mar;96(3):737-45. doi: 10.1210/jc.2010-2435. Epub 2011 Jan 20. J Clin Endocrinol Metab. 2011. PMID: 21252240

9

Glucagon antagonism as a potential therapeutic target in type 2 diabetes.

Bagger JI, Knop FK, Holst JJ, Vilsbøll T. Bagger JI, et al. Among authors: knop fk. Diabetes Obes Metab. 2011 Nov;13(11):965-71. doi: 10.1111/j.1463-1326.2011.01427.x. Diabetes Obes Metab. 2011. PMID: 21615669 Review.

10

Regulation of glucagon secretion by incretins.

Holst JJ, Christensen M, Lund A, de Heer J, Svendsen B, Kielgast U, Knop FK. Holst JJ, et al. Among authors: knop fk. Diabetes Obes Metab. 2011 Oct;13 Suppl 1:89-94. doi: 10.1111/j.1463-1326.2011.01452.x. Diabetes Obes Metab. 2011. PMID: 21824261 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

533 results

Search Page

Filters